GlassScriptPhysician profile
John P Tabacco
NPI 1437443330
$1,690.58
in general payments reported to CMS, 2019-2025
23 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $53.36 · 2021: $11.07 · 2022: $222 · 2023: $486 · 2024: $363 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $315.57 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $281.35 | 2022-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $163.68 | 2020-2025 | |
| Amgen INC. | $138.17 | 2023-2025 | Otezla, Repatha, Otezla |
| Horizon Therapeutics Plc | $99.72 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.12 | 2025 | Xifaxan |
| Astellas Pharma US INC | $67.89 | 2023-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $66.35 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $64.86 | 2023-2025 | Camzyos, Eliquis |
| Lilly USA, LLC | $51.95 | 2024 | Zepbound, Mounjaro |
| Gilead Sciences, INC. | $48.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.58 | 2023-2024 | Jardiance |
| Esperion Therapeutics, INC. | $39.52 | 2022-2023 | Nexletol |
| Nestle Healthcare Nutrition INC. | $33.17 | 2023 | |
| Genentech USA, INC. | $29.48 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $25.26 | 2025 | Aplenzin |
| Abbott Laboratories | $25.19 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $24.14 | 2024 | |
| Becton, Dickinson and Company | $24.10 | 2025 | Bd Max System, Bd Max Instrument |
| Biohaven Pharmaceutical Holding Company LTD. | $23.86 | 2022 | |
| Sumitomo Pharma America, INC. | $23.51 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $15.43 | 2023 | Quviviq |
| Fidia Pharma USA INC. | $13.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tabacco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.